| 1 |
Li S, Chen J, Chen X, Yu J, Guo Y, Li M, Pu X. Therapeutic and prognostic potential of GPCRs in prostate cancer from multi-omics landscape. Front Pharmacol 2022;13:997664. [DOI: 10.3389/fphar.2022.997664] [Reference Citation Analysis]
|
| 2 |
Han MG, Wee CW, Kang MH, Kim MJ, Jeon SH, Kim IA. Combination of OX40 Co-Stimulation, Radiotherapy, and PD-1 Inhibition in a Syngeneic Murine Triple-Negative Breast Cancer Model. Cancers (Basel) 2022;14:2692. [PMID: 35681672 DOI: 10.3390/cancers14112692] [Reference Citation Analysis]
|
| 3 |
Kattan WE, Liu J, Montufar-Solis D, Liang H, Brahmendra Barathi B, van der Hoeven R, Zhou Y, Hancock JF. Components of the phosphatidylserine endoplasmic reticulum to plasma membrane transport mechanism as targets for KRAS inhibition in pancreatic cancer. Proc Natl Acad Sci U S A 2021;118:e2114126118. [PMID: 34903667 DOI: 10.1073/pnas.2114126118] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 4 |
Braun C, Parks XX, Qudsi H, Lopes CMB. Membrane pools of phosphatidylinositol-4-phosphate regulate KCNQ1/KCNE1 membrane expression. Commun Biol 2021;4:1392. [PMID: 34907346 DOI: 10.1038/s42003-021-02909-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 5 |
Szlendak U, Krzymieniewska B, Mendek-Czajkowska E, Rogatko-Koroś M, Witkowska A, Włodarska J, Drozd-Sokołowska J, Spychalska J, Budziszewska B, Patkowska E, Woźniak J, Krzywdzińska A, Jurek S, Juszczyński P, Jaworska M, Rosłon M, Gruber-Bzura B, Wasilewski R, Baran B, Windyga J, Nowak J. Persistent imbalance, anti-apoptotic, and anti-inflammatory signature of circulating C-C chemokines and cytokines in patients with paroxysmal nocturnal hemoglobinuria. Cytokine 2021;150:155780. [PMID: 34896730 DOI: 10.1016/j.cyto.2021.155780] [Reference Citation Analysis]
|
| 6 |
Adhikari H, Kattan WE, Kumar S, Zhou P, Hancock JF, Counter CM. Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity. Nat Commun 2021;12:5248. [PMID: 34504076 DOI: 10.1038/s41467-021-25523-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 7 |
Chang WI, Han MG, Kang MH, Park JM, Kim EE, Bae J, Ahn S, Kim IA. PI3Kαδ Inhibitor Combined With Radiation Enhances the Antitumor Immune Effect of Anti-PD1 in a Syngeneic Murine Triple-Negative Breast Cancer Model. Int J Radiat Oncol Biol Phys 2021;110:845-58. [PMID: 33642128 DOI: 10.1016/j.ijrobp.2021.01.025] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 8 |
Li YP, Mikrani R, Hu YF, Faran Ashraf Baig MM, Abbas M, Akhtar F, Xu M. Research progress of phosphatidylinositol 4-kinase and its inhibitors in inflammatory diseases. Eur J Pharmacol 2021;907:174300. [PMID: 34217706 DOI: 10.1016/j.ejphar.2021.174300] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
Kattan WE, Hancock JF. RAS Function in cancer cells: translating membrane biology and biochemistry into new therapeutics. Biochem J 2020;477:2893-919. [PMID: 32797215 DOI: 10.1042/BCJ20190839] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 10 |
Jabbarzadeh Kaboli P, Salimian F, Aghapour S, Xiang S, Zhao Q, Li M, Wu X, Du F, Zhao Y, Shen J, Cho CH, Xiao Z. Akt-targeted therapy as a promising strategy to overcome drug resistance in breast cancer - A comprehensive review from chemotherapy to immunotherapy. Pharmacol Res 2020;156:104806. [PMID: 32294525 DOI: 10.1016/j.phrs.2020.104806] [Cited by in Crossref: 53] [Cited by in F6Publishing: 58] [Article Influence: 17.7] [Reference Citation Analysis]
|
| 11 |
Kattan WE, Chen W, Ma X, Lan TH, van der Hoeven D, van der Hoeven R, Hancock JF. Targeting plasma membrane phosphatidylserine content to inhibit oncogenic KRAS function. Life Sci Alliance 2019;2:e201900431. [PMID: 31451509 DOI: 10.26508/lsa.201900431] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 12 |
Escors D, Gato-Cañas M, Zuazo M, Arasanz H, García-Granda MJ, Vera R, Kochan G. The intracellular signalosome of PD-L1 in cancer cells. Signal Transduct Target Ther 2018;3:26. [PMID: 30275987 DOI: 10.1038/s41392-018-0022-9] [Cited by in Crossref: 120] [Cited by in F6Publishing: 127] [Article Influence: 24.0] [Reference Citation Analysis]
|
